[{"address1": "321 Harrison Avenue", "address2": "11th Floor, Suite 1", "city": "Boston", "state": "MA", "zip": "02118", "country": "United States", "phone": "617 453 3596", "website": "https://www.pyxisoncology.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat solid tumors. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors. The company is also developing PYX-107, a CD40 agonist with demonstrated anti-cancer activity in patients with several cancer indications, which is in Phase 2 clinical trial for the treatment of tumors, such as soft tissue sarcomas, esophageal and gastroesophageal junction, cancers, and pancreatic ductal adenocarcinoma. It has in-license agreement with Pfizer Inc. to develop and commercialize ADC product candidates, including micvotabart pelidotin and PYX-203, and other ADC product candidates directed to the licensed targets; and Biosion USA, Inc. for development, manufacture, and commercialization of PYX-106, an IO product candidate. Pyxis Oncology, Inc. was incorporated in 2018 and is headquartered in Boston, Massachusetts.", "fullTimeEmployees": 44, "companyOfficers": [{"maxAge": 1, "name": "Dr. Lara S. Sullivan M.D., MBA", "title": "CEO, President, Chief Medical Officer & Director", "fiscalYear": 2024, "totalPay": 1057225, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Pamela Yanchik Connealy M.B.A.", "age": 62, "title": "CFO & COO", "yearBorn": 1962, "fiscalYear": 2024, "totalPay": 763830, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Jitendra  Wadhane C.A., CPA", "age": 43, "title": "Chief Accounting Officer, Senior VP of Finance & Corporate Controller", "yearBorn": 1981, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Balu N. Balasubramanian Ph.D.", "title": "Interim Chief Technology Officer", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Jan  Pinkas Ph.D.", "title": "Chief Scientific Officer", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Charles T. Gombar Ph.D.", "title": "Senior Vice President of Portfolio & Program Management", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Stephen T. Worsley MBA", "age": 60, "title": "Senior VP & Chief Business Officer", "yearBorn": 1964, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Michael  Bui", "title": "Head of Global Regulatory Affairs", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Supriya  Roth Ph.D.", "title": "Head of Commercial Development", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Shui  He Ph.D.", "title": "Head of Biometrics", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 7, "boardRisk": 9, "compensationRisk": 10, "shareHolderRightsRisk": 9, "overallRisk": 10, "governanceEpochDate": 1748736000, "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 4, "previousClose": 1.14, "open": 1.16, "dayLow": 1.14, "dayHigh": 1.19, "regularMarketPreviousClose": 1.14, "regularMarketOpen": 1.16, "regularMarketDayLow": 1.14, "regularMarketDayHigh": 1.19, "payoutRatio": 0.0, "beta": 1.18, "forwardPE": -0.9831932, "volume": 348039, "regularMarketVolume": 348039, "averageVolume": 467391, "averageVolume10days": 412750, "averageDailyVolume10Day": 412750, "bid": 1.12, "ask": 1.21, "bidSize": 1, "askSize": 1, "marketCap": 72478808, "fiftyTwoWeekLow": 0.833, "fiftyTwoWeekHigh": 5.39, "priceToSalesTrailing12Months": "Infinity", "fiftyDayAverage": 1.14156, "twoHundredDayAverage": 1.998575, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": -13111232, "profitMargins": 0.0, "floatShares": 44649399, "sharesOutstanding": 61947700, "sharesShort": 6472521, "sharesShortPriorMonth": 7233818, "sharesShortPreviousMonthDate": 1745971200, "dateShortInterest": 1748563200, "sharesPercentSharesOut": 0.104499996, "heldPercentInsiders": 0.23412001, "heldPercentInstitutions": 0.3825, "shortRatio": 14.49, "shortPercentOfFloat": 0.1265, "impliedSharesOutstanding": 64664700, "bookValue": 1.673, "priceToBook": 0.6993425, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1743379200, "netIncomeToCommon": -95233000, "trailingEps": -1.61, "forwardEps": -1.19, "enterpriseToEbitda": 0.162, "52WeekChange": -0.63322884, "SandP52WeekChange": 0.09544468, "quoteType": "EQUITY", "currentPrice": 1.17, "targetHighPrice": 8.0, "targetLowPrice": 5.0, "targetMeanPrice": 6.2, "targetMedianPrice": 6.0, "recommendationKey": "none", "numberOfAnalystOpinions": 5, "totalCash": 105432000, "totalCashPerShare": 1.702, "ebitda": -80745000, "totalDebt": 19842000, "quickRatio": 7.306, "currentRatio": 7.753, "totalRevenue": 0, "debtToEquity": 19.245, "revenuePerShare": 0.0, "returnOnAssets": -0.29193002, "returnOnEquity": -0.66305, "grossProfits": 0, "freeCashflow": -28588876, "operatingCashflow": -59497000, "grossMargins": 0.0, "ebitdaMargins": 0.0, "operatingMargins": 0.0, "financialCurrency": "USD", "symbol": "PYXS", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Delayed Quote", "triggerable": true, "customPriceAlertConfidence": "HIGH", "shortName": "Pyxis Oncology, Inc.", "marketState": "CLOSED", "regularMarketChangePercent": 2.63158, "regularMarketPrice": 1.17, "twoHundredDayAverageChange": -0.828575, "twoHundredDayAverageChangePercent": -0.4145829, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "ipoExpectedDate": "2021-10-08", "cryptoTradeable": false, "exchange": "NMS", "messageBoardId": "finmb_629268721", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "longName": "Pyxis Oncology, Inc.", "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1633699800000, "postMarketChangePercent": 0.0, "postMarketPrice": 1.17, "postMarketChange": 0.0, "regularMarketChange": 0.03, "regularMarketDayRange": "1.14 - 1.19", "fullExchangeName": "NasdaqGS", "averageDailyVolume3Month": 467391, "fiftyTwoWeekLowChange": 0.33699995, "fiftyTwoWeekLowChangePercent": 0.40456176, "fiftyTwoWeekRange": "0.833 - 5.39", "fiftyTwoWeekHighChange": -4.22, "fiftyTwoWeekHighChangePercent": -0.7829313, "fiftyTwoWeekChangePercent": -63.322884, "earningsTimestamp": 1747306800, "earningsTimestampStart": 1754996340, "earningsTimestampEnd": 1755518400, "isEarningsDateEstimate": true, "epsTrailingTwelveMonths": -1.61, "epsForward": -1.19, "epsCurrentYear": -1.4, "priceEpsCurrentYear": -0.8357143, "fiftyDayAverageChange": 0.028439999, "fiftyDayAverageChangePercent": 0.024913276, "corporateActions": [], "postMarketTime": 1750449843, "regularMarketTime": 1750449601, "displayName": "Pyxis Oncology", "trailingPegRatio": null, "__fetch_time": "2025-06-21"}]